{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:22:01Z","timestamp":1771734121923,"version":"3.50.1"},"posted":{"date-parts":[[2025,9,5]]},"group-title":"In Review","reference-count":98,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,1]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <italic>Candida<\/italic>\n                  species, including\n                  <italic>Candida albicans<\/italic>\n                  and\n                  <italic>Candida auris<\/italic>\n                  , represent a growing public health concern due to their increasing prevalence and resistance to antifungal agents.\n                  <italic>C. albicans<\/italic>\n                  is known for causing both superficial and invasive infections, while\n                  <italic>C. auris<\/italic>\n                  is a newly emerged, multidrug-resistant pathogen responsible for severe hospital outbreaks with a high mortality rate of ~\u200960% in bloodstream infections. Vaccine candidates targeting\n                  <italic>C. albicans<\/italic>\n                  hyphal cell wall proteins Als3p and Hyr1p have shown protective efficacy in mice. NDV-3A, an alum-formulated Als3p-based vaccine, protects against recurrent vulvovaginal candidiasis in women. We earlier showed that both Als3p and Hyr1p have orthologs in\n                  <italic>C. auris<\/italic>\n                  , and that the NDV-3A vaccine, alongside an anti-Hyr1p monoclonal antibody, protect mice from lethal\n                  <italic>C. auris<\/italic>\n                  candidemia. Here, we optimized Als3p and Hyr1p dual antigen vaccine formulations with the clinical-stage adjuvant CAF01, demonstrating robust immunity and CD4 T cell-dependent protection against lethal\n                  <italic>C. albicans<\/italic>\n                  and\n                  <italic>C. auris<\/italic>\n                  . The vaccine formulations also showed enhanced protective efficacy when combined with antifungal drugs. This study highlights the potential of the CAF01-formulated Als3p\/Hyr1p dual antigen vaccine in providing durable protective immunity against systemic and mucosal\n                  <italic>C. albicans<\/italic>\n                  and cross-protection against systemic multidrug-resistant\n                  <italic>C. auris<\/italic>\n                  infections.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7270678\/v1","type":"posted-content","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T13:12:43Z","timestamp":1757077963000},"source":"Crossref","is-referenced-by-count":2,"title":["Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections"],"prefix":"10.21203","author":[{"given":"Shakti","family":"Singh","sequence":"first","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman G.","family":"Youssef","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Barbarino","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Hautau","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunna","family":"Nabeela","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teclegiorgis","family":"Gebremariam","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sondus","family":"Alkhazraji","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Ostroff","sequence":"additional","affiliation":[{"name":"University of Massachusetts Chan Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Christensen","sequence":"additional","affiliation":[{"name":"Croda Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence","family":"Cochrane","sequence":"additional","affiliation":[{"name":"Vitalex Biosciences LLC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor-UCLA Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1086\/520194","article-title":"National Epidemiology of Mycoses Survey (NEMIS): Variations in Rates of Bloodstream Infections Due to Candida Species in Seven Surgical Intensive Care Units and Six Neonatal Intensive Care Units","volume":"29","author":"Rangel-Frausto MS","year":"1999","unstructured":"Rangel-Frausto, M. S. et al. National Epidemiology of Mycoses Survey (NEMIS): Variations in Rates of Bloodstream Infections Due to Candida Species in Seven Surgical Intensive Care Units and Six Neonatal Intensive Care Units. Clin. Infect. Dis. 29, 253\u2013258. 10.1086\/520194 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1086\/507539","article-title":"Emerging Infections: In Harm\u2019s Way: Infections in Deployed American Military Forces","volume":"43","author":"Aronson NE","year":"2006","unstructured":"Aronson, N. E., Sanders, J. W. & Moran, K. A. Emerging Infections: In Harm\u2019s Way: Infections in Deployed American Military Forces. Clin. Infect. Dis. 43, 1045\u20131051. 10.1086\/507539 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.7205\/milmed.170.6.521","article-title":"Aeromedical Evacuations from Operation Iraqi Freedom: A Descriptive Study","volume":"170","author":"Harman DR","year":"2005","unstructured":"Harman, D. R., Hooper, T. I. & Gackstetter, G. D. Aeromedical Evacuations from Operation Iraqi Freedom: A Descriptive Study. Mil Med. 170, 521\u2013527. 10.7205\/milmed.170.6.521 (2005).","journal-title":"Mil Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/jramc-152-02-06","article-title":"Ballistic Fractures During The 2003 Gulf Conflict - Early Prognosis And High Complication Rate","volume":"152","author":"Hinsley DE","year":"2006","unstructured":"Hinsley, D. E., Phillips, S. & Clasper, J. C. Ballistic Fractures During The 2003 Gulf Conflict - Early Prognosis And High Complication Rate. J. R Army Med. Corps. 152, 96\u2013101. 10.1136\/jramc-152-02-06 (2006).","journal-title":"J. R Army Med. Corps"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7205\/milmed.171.9.826","article-title":"Bacteriology of War Wounds at the Time of Injury","volume":"171","author":"Murray CK","year":"2006","unstructured":"Murray, C. K. et al. Bacteriology of War Wounds at the Time of Injury. Mil Med. 171, 826\u2013829. 10.7205\/milmed.171.9.826 (2006).","journal-title":"Mil Med."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.7205\/milmed-d-03-8008","article-title":"Recovery of Multidrug-Resistant Bacteria From Combat Personnel Evacuated From Iraq and Afghanistan at a Single Military Treatment Facility","volume":"174","author":"Murray CK","year":"2009","unstructured":"Murray, C. K. et al. Recovery of Multidrug-Resistant Bacteria From Combat Personnel Evacuated From Iraq and Afghanistan at a Single Military Treatment Facility. Mil Med. 174, 598\u2013604. 10.7205\/milmed-d-03-8008 (2009).","journal-title":"Mil Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajic.2009.05.007","article-title":"Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility","volume":"38","author":"Perez F","year":"2010","unstructured":"Perez, F. et al. Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am. J. Infect. Control. 38, 63\u201365. 10.1016\/j.ajic.2009.05.007 (2010). 2009\/09\/24.","journal-title":"Am. J. Infect. Control"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10096-003-0890-x","article-title":"Candidemia in a tertiary care hospital: Epidemiology and factors influencing mortality","volume":"22","author":"Alonso-Valle H","year":"2003","unstructured":"Alonso-Valle, H. et al. Candidemia in a tertiary care hospital: Epidemiology and factors influencing mortality. Eur. J. Clin. Microbiol. Infect. Dis. 22, 254\u2013257. 10.1007\/s10096-003-0890-x (2003).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1086\/374621","article-title":"Population-Based Study of the Epidemiology of and the Risk Factors for Invasive Staphylococcus aureus Infections","volume":"187","author":"Laupland KB","year":"2003","unstructured":"Laupland, K. B., Church, D. L., Mucenski, M., Sutherland, L. R. & Davies, H. D. Population-Based Study of the Epidemiology of and the Risk Factors for Invasive Staphylococcus aureus Infections. J. Infect. Dis. 187, 1452\u20131459. 10.1086\/374621 (2003).","journal-title":"J. Infect. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/archinte.159.13.1437","article-title":"Risk Factors for Hospital-Acquired Staphylococcus aureus Bacteremia","volume":"159","author":"Jensen AG","year":"1999","unstructured":"Jensen, A. G. et al. Risk Factors for Hospital-Acquired Staphylococcus aureus Bacteremia. Arch. Intern. Med. 159, 1437. 10.1001\/archinte.159.13.1437 (1999).","journal-title":"Arch. Intern. Med."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s100960000325","article-title":"Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital","volume":"19","author":"Luzzati R","year":"2000","unstructured":"Luzzati, R. et al. Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital. Eur. J. Clin. Microbiol. Infect. Dis. 19, 602\u2013607. 10.1007\/s100960000325 (2000).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/archsurg.136.12.1401","article-title":"Temporal Assessment of Candida Risk Factors in the Surgical Intensive Care Unit","volume":"136","author":"McKinnon PS","year":"2001","unstructured":"McKinnon, P. S. Temporal Assessment of Candida Risk Factors in the Surgical Intensive Care Unit. Arch. Surg. 136, 1401. 10.1001\/archsurg.136.12.1401 (2001).","journal-title":"Arch. Surg."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3109\/00365549409008638","article-title":"Candidemia: Current Epidemiologic Characteristics and a Long-term Follow-up of the Survivors","volume":"26","author":"Debusk CH","year":"1994","unstructured":"Debusk, C. H., Daoud, R., Thirumoorthi, M. C., Wilson, F. M. & Khatib, R. Candidemia: Current Epidemiologic Characteristics and a Long-term Follow-up of the Survivors. Scand. J. Infect. Dis. 26, 697\u2013703. 10.3109\/00365549409008638 (1994).","journal-title":"Scand. J. Infect. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00134-003-2002-x","article-title":"Candidemia in critically ill patients: difference of outcome between medical and surgical patients","volume":"29","author":"Charles PE","year":"2003","unstructured":"Charles, P. E. et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 29, 2162\u20132169. 10.1007\/s00134-003-2002-x (2003).","journal-title":"Intensive Care Med."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.13.18-00136","article-title":"Candida auris: Epidemiological situation, laboratory capacity and preparedness in European Union and European economic area countries, 2013 to 2017","volume":"23","author":"Kohlenberg A","year":"2018","unstructured":"Kohlenberg, A. et al. Candida auris: Epidemiological situation, laboratory capacity and preparedness in European Union and European economic area countries, 2013 to 2017. Eurosurveillance 23 10.2807\/1560-7917.ES.2018.23.13.18-00136 (2018).","journal-title":"Eurosurveillance"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1128\/AAC.04867-14","article-title":"Candida infective endocarditis: An observational cohort study with a focus on therapy","volume":"59","author":"Arnold CJ","year":"2015","unstructured":"Arnold, C. J. et al. Candida infective endocarditis: An observational cohort study with a focus on therapy. Antimicrob. Agents Chemother. 59, 2365\u20132373. 10.1128\/AAC.04867-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1128\/JCM.43.4.1829-1835.2005","article-title":"Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003","volume":"43","author":"Almirante B","year":"2005","unstructured":"Almirante, B. et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43, 1829\u20131835. 10.1128\/JCM.43.4.1829-1835.2005 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1007\/s00134-009-1582-5","article-title":"Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients","volume":"35","author":"Caricato A","year":"2009","unstructured":"Caricato, A. et al. Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients. Intensive Care Med. 35, 1964\u20131969. 10.1007\/s00134-009-1582-5 (2009).","journal-title":"Intensive Care Med."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1445-5994.2005.00925.x","article-title":"Mortality risk factors of Acinetobacter baumannii bacteraemia","volume":"35","author":"Choi JY","year":"2005","unstructured":"Choi, J. Y. et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern. Med. J. 35, 599\u2013603. 10.1111\/j.1445-5994.2005.00925.x (2005).","journal-title":"Intern. Med. J."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1179\/joc.2009.21.3.290","article-title":"Acinetobacter baumannii: Emergence of Four Strains with NovelblaOXA\u201351\u2013likeGenes in Patients with Diabetes Mellitus","volume":"21","author":"Alsultan AA","year":"2009","unstructured":"Alsultan, A. A., Hamouda, A., Evans, B. A. & Amyes, S. G. B. Acinetobacter baumannii: Emergence of Four Strains with NovelblaOXA\u201351\u2013likeGenes in Patients with Diabetes Mellitus. J. Chemother. 21, 290\u2013295. 10.1179\/joc.2009.21.3.290 (2009).","journal-title":"J. Chemother."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1590\/s1413-86702012000300004","article-title":"Factors influencing survival in patients with multidrug-resistant Acinetobacter baumannii infection","volume":"16","author":"Prata-Rocha ML","year":"2012","unstructured":"Prata-Rocha, M. L., Gontijo-Filho, P. P. & de Melo, G. B. Factors influencing survival in patients with multidrug-resistant Acinetobacter baumannii infection. Brazilian J. Infect. Dis. 16, 237\u2013241. 10.1590\/s1413-86702012000300004 (2012).","journal-title":"Brazilian J. Infect. Dis."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s0891-5520(05)70363-9","article-title":"Nosocomial Candida","volume":"11","author":"Wright WL","year":"1997","unstructured":"Wright, W. L. & Wenzel, R. P. Nosocomial Candida. Infect. Dis. Clin. North. Am. 11, 411\u2013425. 10.1016\/s0891-5520(05)70363-9 (1997).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3201\/eid1301.060716","article-title":"Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization","volume":"13","author":"Sunenshine RH","year":"2007","unstructured":"Sunenshine, R. H. et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis. 13, 97\u2013103. 10.3201\/eid1301.060716 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/003655401750065544","article-title":"Candidemia Before and During the Fluconazole Era: Prevalence, Type of Species and Approach to Treatment in a Tertiary Care Community Hospital","volume":"33","author":"Joseph Baran BM","year":"2001","unstructured":"Joseph Baran, B. M. Jr Candidemia Before and During the Fluconazole Era: Prevalence, Type of Species and Approach to Treatment in a Tertiary Care Community Hospital. Scand. J. Infect. Dis. 33, 137\u2013139. 10.1080\/003655401750065544 (2001).","journal-title":"Scand. J. Infect. Dis."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archsurg.134.6.657","article-title":"Candida Infections in Critically Ill Trauma Patients","volume":"134","author":"Borzotta AP","year":"1999","unstructured":"Borzotta, A. P. Candida Infections in Critically Ill Trauma Patients. Arch. Surg. 134, 657. 10.1001\/archsurg.134.6.657 (1999).","journal-title":"Arch. Surg."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/s0002-9343(89)80392-4","article-title":"Risk factors for nosocomial candidemia: A case-control study in adults without leukemia","volume":"87","author":"Bross J","year":"1989","unstructured":"Bross, J., Talbot, G. H., Maislin, G., Hurwitz, S. & Strom, B. L. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am. J. Med. 87, 614\u2013620. 10.1016\/s0002-9343(89)80392-4 (1989).","journal-title":"Am. J. Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/clind\/15.3.414","article-title":"Candidemia in a Tertiary Care Hospital: Epidemiology, Risk Factors, and Predictors of Mortality","volume":"15","author":"Fraser VJ","year":"1992","unstructured":"Fraser, V. J. et al. Candidemia in a Tertiary Care Hospital: Epidemiology, Risk Factors, and Predictors of Mortality. Clin. Infect. Dis. 15, 414\u2013421. 10.1093\/clind\/15.3.414 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1086\/313450","article-title":"The Epidemiology of Candidemia in Two United States Cities: Results of a Population-Based Active Surveillance","volume":"29","author":"Kao AS","year":"1999","unstructured":"Kao, A. S. et al. The Epidemiology of Candidemia in Two United States Cities: Results of a Population-Based Active Surveillance. Clin. Infect. Dis. 29, 1164\u20131170. 10.1086\/313450 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s001340050286","article-title":"Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy","volume":"23","author":"Nolla-Salas J","year":"1997","unstructured":"Nolla-Salas, J. et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med. 23, 23\u201330. 10.1007\/s001340050286 (1997).","journal-title":"Intensive Care Med."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/ajrccm.156.2.9612023","article-title":"Significance of the Isolation of Candida Species from Respiratory Samples in Critically Ill, Non-neutropenic Patients","volume":"156","author":"El-Ebiary M","year":"1997","unstructured":"El-Ebiary, M. et al. Significance of the Isolation of Candida Species from Respiratory Samples in Critically Ill, Non-neutropenic Patients. Am. J. Respir Crit. Care Med. 156, 583\u2013590. 10.1164\/ajrccm.156.2.9612023 (1997).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1099\/jmm.0.000254","article-title":"Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery","volume":"65","author":"Silva KE","year":"2016","unstructured":"da Silva, K. E. et al. Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery. J. Med. Microbiol. 65, 547\u2013553. 10.1099\/jmm.0.000254 (2016).","journal-title":"J. Med. Microbiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.bjid.2012.08.006","article-title":"Risk factors for KPC-producing Klebsiella pneumoniae bacteremia","volume":"16","author":"Tuon FF","year":"2012","unstructured":"Tuon, F. F. et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Brazilian J. Infect. Dis. 16, 416\u2013419. 10.1016\/j.bjid.2012.08.006 (2012).","journal-title":"Brazilian J. Infect. Dis."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhin.2017.02.010","article-title":"Risk factors for KPC-producing Enterobacteriaceae acquisition and infection in a healthcare setting with possible local transmission: a case\u2013control study","volume":"96","author":"Cronin KM","year":"2017","unstructured":"Cronin, K. M. et al. Risk factors for KPC-producing Enterobacteriaceae acquisition and infection in a healthcare setting with possible local transmission: a case\u2013control study. J. Hosp. Infect. 96, 111\u2013115. 10.1016\/j.jhin.2017.02.010 (2017).","journal-title":"J. Hosp. Infect."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1155\/2011\/827692","article-title":"Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia","volume":"18","author":"Delisle M-S","year":"2011","unstructured":"Delisle, M-S. et al. Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia. Can. Respir J. 18, 131\u2013136. 10.1155\/2011\/827692 (2011).","journal-title":"Can. Respir J."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1086\/374339","article-title":"Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States","volume":"36","author":"Wisplinghoff H","year":"2003","unstructured":"Wisplinghoff, H., Seifert, H., Wenzel, R. P. & Edmond, M. B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis. 36, 1103\u20131110. 10.1086\/374339 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff H","year":"2004","unstructured":"Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309\u2013317. 10.1086\/421946 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/01.inf.0000078159.53132.40","article-title":"Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities","volume":"22","author":"Wisplinghoff H","year":"2003","unstructured":"Wisplinghoff, H. et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22, 686\u2013691. 10.1097\/01.inf.0000078159.53132.40 (2003).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/23744235.2019.1662941","article-title":"Clinical and microbiological factors associated with mortality in candidemia in adult patients 2007\u20132016","volume":"51","author":"Ala-Houhala M","year":"2019","unstructured":"Ala-Houhala, M., Valkonen, M., Kolho, E., Friberg, N. & Anttila, V-J. Clinical and microbiological factors associated with mortality in candidemia in adult patients 2007\u20132016. Infect. Dis. (Lond). 51, 824\u2013830. 10.1080\/23744235.2019.1662941 (2019).","journal-title":"Infect. Dis. (Lond)"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010)","volume":"40","author":"Lortholary O","year":"2014","unstructured":"Lortholary, O. et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010). Intensive Care Med. 40, 1303\u20131312. 10.1007\/s00134-014-3408-3 (2014).","journal-title":"Intensive Care Med."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/319613","article-title":"Estimating the Cost of Nosocomial Candidemia in the United States","volume":"32","author":"Miller LG","year":"2001","unstructured":"Miller, L. G., Hajjeh, R. A. & Edwards, J. E. Estimating the Cost of Nosocomial Candidemia in the United States. Clin. Infect. Dis. 32, 1110\u20131110. 10.1086\/319613 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","article-title":"The Direct Cost and Incidence of Systemic Fungal Infections","volume":"5","author":"Wilson LS","year":"2002","unstructured":"Wilson, L. S. et al. The Direct Cost and Incidence of Systemic Fungal Infections. Value Health. 5, 26\u201334. 10.1046\/j.1524-4733.2002.51108.x (2002).","journal-title":"Value Health"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/496922","article-title":"The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis","volume":"41","author":"Zaoutis TE","year":"2005","unstructured":"Zaoutis, T. E. et al. The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis. Clin. Infect. Dis. 41, 1232\u20131239. 10.1086\/496922 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jgar.2020.06.003","article-title":"The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic","volume":"22","author":"Chowdhary A","year":"2020","unstructured":"Chowdhary, A. & Sharma, A. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J. Glob Antimicrob. Resist. 22, 175\u2013176. 10.1016\/j.jgar.2020.06.003 (2020).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart SR","year":"2017","unstructured":"Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 64, 134\u2013140. 10.1093\/cid\/ciw691 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0196-6553(82)90003-7","article-title":"The global eradication of smallpox","volume":"10","author":"Strassburg MA","year":"1982","unstructured":"Strassburg, M. A. The global eradication of smallpox. Am. J. Infect. Control. 10, 53\u201359. 10.1016\/0196-6553(82)90003-7 (1982).","journal-title":"Am. J. Infect. Control"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/EC.00279-10","article-title":"Candida albicans Als3, a multifunctional adhesin and invasin","volume":"10","author":"Liu Y","year":"2011","unstructured":"Liu, Y. & Filler, S. G. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot. Cell. 10, 168\u2013173. 10.1128\/EC.00279-10 (2011).","journal-title":"Eukaryot. Cell."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1371\/journal.pbio.0050064","article-title":"Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells","volume":"5","author":"Phan QT","year":"2007","unstructured":"Phan, Q. T. et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol. 5, e64. 10.1371\/journal.pbio.0050064 (2007).","journal-title":"PLoS Biol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/IAI.00013-13","article-title":"Investigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrata","volume":"81","author":"Fu Y","year":"2013","unstructured":"Fu, Y. et al. Investigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrata. Infect. Immun. 81, 2528\u20132535. 10.1128\/IAI.00013-13 (2013).","journal-title":"Infect. Immun."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1086\/652407","article-title":"Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target","volume":"201","author":"Luo G","year":"2010","unstructured":"Luo, G. et al. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J. Infect. Dis. 201, 1718\u20131728. 10.1086\/652407 (2010).","journal-title":"J. Infect. Dis."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1016\/j.vaccine.2013.09.016","article-title":"NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response","volume":"31","author":"Ibrahim AS","year":"2013","unstructured":"Ibrahim, A. S. et al. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 31, 5549\u20135556. 10.1016\/j.vaccine.2013.09.016 (2013).","journal-title":"Vaccine"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/cid\/ciy185","article-title":"A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial","volume":"66","author":"Edwards JE","year":"2018","unstructured":"Edwards, J. E. et al. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases. 2018\/04\/27. ;66: 1928\u20131936. (2018). 10.1093\/cid\/ciy185"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e1007460","DOI":"10.1371\/journal.ppat.1007460","article-title":"The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection","volume":"15","author":"Singh S","year":"2019","unstructured":"Singh, S. et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathog. 15, e1007460. 10.1371\/journal.ppat.1007460 (2019).","journal-title":"PLoS Pathog"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/iyad024","article-title":"Parallel expansion and divergence of an adhesin family in pathogenic yeasts","volume":"223","author":"Smoak RA","year":"2023","unstructured":"Smoak, R. A., Snyder, L. F., Fassler, J. S. & He, B. Z. Parallel expansion and divergence of an adhesin family in pathogenic yeasts. Genetics 223 10.1093\/genetics\/iyad024 (2023).","journal-title":"Genetics"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/jof9010103","article-title":"Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris","volume":"9","author":"Singh S","year":"2023","unstructured":"Singh, S. et al. Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris. J. Fungi (Basel). 9 10.3390\/jof9010103 (2023).","journal-title":"J. Fungi (Basel)"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/s41467-018-07738-1","article-title":"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis","volume":"9","author":"Rudkin FM","year":"2018","unstructured":"Rudkin, F. M. et al. Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat. Commun. 9, 5288. 10.1038\/s41467-018-07738-1 (2018).","journal-title":"Nat. Commun."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PPAT.1011239","article-title":"Clinical isolates of Candida auris with enhanced adherence and biofilm formation due to genomic amplification of ALS4","volume":"19","author":"Bing J","year":"2023","unstructured":"Bing, J. et al. Clinical isolates of Candida auris with enhanced adherence and biofilm formation due to genomic amplification of ALS4. PLoS Pathog. 19 10.1371\/JOURNAL.PPAT.1011239 (2023).","journal-title":"PLoS Pathog"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"9212","DOI":"10.1038\/S41467-024-53588-5","article-title":"Functional redundancy in Candida auris cell surface adhesins crucial for cell-cell interaction and aggregation","volume":"15","author":"Wang TW","year":"2024","unstructured":"Wang, T. W. et al. Functional redundancy in Candida auris cell surface adhesins crucial for cell-cell interaction and aggregation. Nat. Commun. 15, 9212. 10.1038\/S41467-024-53588-5 (2024).","journal-title":"Nat. Commun."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.adf8972","article-title":"A Candida auris-specific adhesin, Scf1, governs surface association, colonization, and virulence","volume":"381","author":"Santana DJ","year":"2023","unstructured":"Santana, D. J. et al. A Candida auris-specific adhesin, Scf1, governs surface association, colonization, and virulence. Science 381, 1461\u20131467. 10.1126\/science.adf8972 (2023).","journal-title":"Science"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/iyad024","author":"Smoak RA","year":"2023","unstructured":"Smoak, R. A., Snyder, L. F., Fassler, J. S. & He, B. Z. Parallel expansion and divergence of an adhesin family in pathogenic yeasts. Mitchell A, editor. Genetics. ;223. (2023). 10.1093\/genetics\/iyad024"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/B978-0-12-804019-5.00017-7","article-title":"Development and Evaluation of CAF01. Immunopotentiators in Modern Vaccines","author":"Christensen D","year":"2017","unstructured":"Christensen, D. Development and Evaluation of CAF01. Immunopotentiators in Modern Vaccines. Second Ed. 333\u2013345. 10.1016\/B978-0-12-804019-5.00017-7 (2017).","journal-title":"Second Ed."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"Dissel JT","year":"2014","unstructured":"van Dissel, J. T. et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32, 7098\u20137107. 10.1016\/j.vaccine.2014.10.036 (2014).","journal-title":"Vaccine"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.1038\/S41598-022-13819-5","article-title":"Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters","volume":"12","author":"Stark FC","year":"2022","unstructured":"Stark, F. C. et al. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. Sci. Rep. 12, 9772. 10.1038\/S41598-022-13819-5 (2022).","journal-title":"Sci. Rep."},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00070-18","article-title":"Glucan-chitin particles enhance Th17 response and improve protective efficacy of a multivalent antigen (rCpa1) against pulmonary Coccidioides posadasii infection","volume":"86","author":"Hung CY","year":"2018","unstructured":"Hung, C. Y. et al. Glucan-chitin particles enhance Th17 response and improve protective efficacy of a multivalent antigen (rCpa1) against pulmonary Coccidioides posadasii infection. Infect. Immun. 86 10.1128\/IAI.00070-18 (2018).","journal-title":"Infect. Immun."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/0264-410X(95)00089-J","article-title":"Enhancement of humoral response against human influenza vaccine with the simple submicron oil\/water emulsion adjuvant MF59","volume":"13","author":"Ott G","year":"1995","unstructured":"Ott, G., Barchfeld, G. L., Nest, G. & Van Enhancement of humoral response against human influenza vaccine with the simple submicron oil\/water emulsion adjuvant MF59. Vaccine 13, 1557\u20131562. 10.1016\/0264-410X(95)00089-J (1995).","journal-title":"Vaccine"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/0264-410X(93)90376-9","article-title":"Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant","volume":"11","author":"Keitel W","year":"1993","unstructured":"Keitel, W. et al. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11, 909\u2013913. 10.1016\/0264-410X(93)90376-9 (1993).","journal-title":"Vaccine"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1016\/j.vaccine.2013.09.016","article-title":"NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response","volume":"31","author":"Ibrahim AS","year":"2013","unstructured":"Ibrahim, A. S. et al. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 31, 5549\u20135556. 10.1016\/j.vaccine.2013.09.016 (2013). 2013\/09\/26.","journal-title":"Vaccine"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691","author":"Lockhart SR","year":"2016","unstructured":"Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Diseases. 2017;64: 134\u2013140. (2016). \/12\/19 10.1093\/cid\/ciw691"},{"key":"ref68","unstructured":"Centers for Disease Control and Prevention. Screening for Candida auris Colonization | Candida auris | Fungal Diseases | CDC. In: Centers for Disease Control and Prevention. (2019). Available: https:\/\/www.cdc.gov\/fungal\/candida-auris\/c-auris-screening.html"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40560-018-0342-4","article-title":"Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris","volume":"6","author":"Cortegiani A","year":"2018","unstructured":"Cortegiani, A. et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J. Intensive Care. 6, 69. 10.1186\/s40560-018-0342-4 (2018).","journal-title":"J. Intensive Care"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008921","article-title":"Candida auris: Epidemiology, biology, antifungal resistance, and virulence","volume":"16","author":"Du H","year":"2020","unstructured":"Du, H. et al. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 16 10.1371\/journal.ppat.1008921 (2020).","journal-title":"PLoS Pathog"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1128\/IAI.74.5.3039-3041.2006","article-title":"The anti-candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis","volume":"74","author":"Ibrahim AS","year":"2006","unstructured":"Ibrahim, A. S., Spellberg, B. J., Avanesian, V., Fu, Y. & Edwards, J. E. The anti-candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect. Immun. 74, 3039\u20133041. 10.1128\/IAI.74.5.3039-3041.2006 (2006). 2006\/04\/20.","journal-title":"Infect. Immun."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1128\/IAI.73.9.6191-6193.2005","article-title":"The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice","volume":"73","author":"Spellberg BJ","year":"2005","unstructured":"Spellberg, B. J. et al. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect. Immun. 73, 6191\u20136193. 10.1128\/IAI.73.9.6191-6193.2005 (2005).","journal-title":"Infect. Immun."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1086\/652407","article-title":"Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target","volume":"201","author":"Luo G","year":"2010","unstructured":"Luo, G. et al. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J. Infect. Dis. 201, 1718\u20131728. 10.1086\/652407 (2010).","journal-title":"J. Infect. Dis."},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/jof9010103","article-title":"Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris","volume":"9","author":"Singh S","year":"2023","unstructured":"Singh, S. et al. Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris. J. Fungi (Basel). 9 10.3390\/jof9010103 (2023).","journal-title":"J. Fungi (Basel)"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"e1007460","DOI":"10.1371\/journal.ppat.1007460","article-title":"The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. Gaffen SL, editor","volume":"15","author":"Singh S","year":"2019","unstructured":"Singh, S. et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. Gaffen SL, editor. PLoS Pathog. 15, e1007460. 10.1371\/journal.ppat.1007460 (2019).","journal-title":"PLoS Pathog"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00959-22","article-title":"Evaluation of Multivalent Enterotoxigenic Escherichia coli Vaccine Candidate MecVax Antigen Dose-Dependent Effect in a Murine Model","volume":"88","author":"Seo H","year":"2022","unstructured":"Seo, H., Duan, Q., Upadhyay, I. & Zhang, W. Evaluation of Multivalent Enterotoxigenic Escherichia coli Vaccine Candidate MecVax Antigen Dose-Dependent Effect in a Murine Model. Appl. Environ. Microbiol. 88 10.1128\/AEM.00959-22 (2022).","journal-title":"Appl. Environ. Microbiol."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0264-410X(99)00316-3","article-title":"Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines","volume":"18","author":"Kim SK","year":"1999","unstructured":"Kim, S. K. et al. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18, 597\u2013603. 10.1016\/S0264-410X(99)00316-3 (1999).","journal-title":"Vaccine"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/J.VACCINE.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack A","year":"2008","unstructured":"Wack, A. et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26, 552\u2013561. 10.1016\/J.VACCINE.2007.11.054 (2008).","journal-title":"Vaccine"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3389\/fimmu.2018.01349","article-title":"Human Anti-Als3p antibodies are surrogate markers of NDV-3A vaccine efficacy against recurrent vulvovaginal candidiasis","volume":"9","author":"Uppuluri P","year":"2018","unstructured":"Uppuluri, P. et al. Human Anti-Als3p antibodies are surrogate markers of NDV-3A vaccine efficacy against recurrent vulvovaginal candidiasis. Front. Immunol. 9, 1349. 10.3389\/fimmu.2018.01349 (2018).","journal-title":"Front. Immunol."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e0310152","DOI":"10.1371\/JOURNAL.PONE.0310152","article-title":"Effect of vaccine dose intervals: Considering immunity levels, vaccine efficacy, and strain variants for disease control strategy","volume":"19","author":"Ghosh S","year":"2024","unstructured":"Ghosh, S., Banerjee, M. & Chattopadhyay, A. K. Effect of vaccine dose intervals: Considering immunity levels, vaccine efficacy, and strain variants for disease control strategy. PLoS One. 19, e0310152. 10.1371\/JOURNAL.PONE.0310152 (2024).","journal-title":"PLoS One"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/CID\/CIAE559","article-title":"COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection","volume":"80","author":"Townsend JP","year":"2025","unstructured":"Townsend, J. P., Hassler, H. B., Dornburg, A. & Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection. Clin. Infect. Dis. 80, 316\u2013322. 10.1093\/CID\/CIAE559 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/JMV.27637","article-title":"Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS\u2010CoV\u20102 vaccine in mice","volume":"94","author":"Luan N","year":"2022","unstructured":"Luan, N., Wang, Y., Cao, H., Lin, K. & Liu, C. Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS\u2010CoV\u20102 vaccine in mice. J. Med. Virol. 94, 2250. 10.1002\/JMV.27637 (2022).","journal-title":"J. Med. Virol."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"8426","DOI":"10.1038\/S41598-024-58811-3","article-title":"SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series","volume":"14","author":"Korosec CS","year":"2024","unstructured":"Korosec, C. S., Dick, D. W., Moyles, I. R. & Watmough, J. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series. Sci. Rep. 14, 8426. 10.1038\/S41598-024-58811-3 (2024).","journal-title":"Sci. Rep."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/21645515.2018.1527496","article-title":"The effect of antigen dose on T cell-targeting vaccine outcome","volume":"15","author":"Billeskov R","year":"2018","unstructured":"Billeskov, R., Beikzadeh, B. & Berzofsky, J. A. The effect of antigen dose on T cell-targeting vaccine outcome. Hum. Vaccin Immunother. 15, 407. 10.1080\/21645515.2018.1527496 (2018).","journal-title":"Hum. Vaccin Immunother"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.4049\/JIMMUNOL.1600965","article-title":"Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy","volume":"198","author":"Billeskov R","year":"2017","unstructured":"Billeskov, R. et al. Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. J. Immunol. 198, 3494\u20133506. 10.4049\/JIMMUNOL.1600965 (2017).","journal-title":"J. Immunol."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1084\/JEM.132.1.77","article-title":"Studies on the Regulation of Avidity at the Level of the Single Antibody-forming Cell: the Effect of Antigen Dose and Time after Immunization","volume":"132","author":"Andersson B","year":"1970","unstructured":"Andersson, B. Studies on the Regulation of Avidity at the Level of the Single Antibody-forming Cell: the Effect of Antigen Dose and Time after Immunization. J. Exp. Med. 132, 77\u201388. 10.1084\/JEM.132.1.77 (1970).","journal-title":"J. Exp. Med."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/J.MIB.2020.05.006","article-title":"The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine","volume":"56","author":"Kumamoto CA","year":"2020","unstructured":"Kumamoto, C. A., Gresnigt, M. S. & Hube, B. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Curr. Opin. Microbiol. 56, 7\u201315. 10.1016\/J.MIB.2020.05.006 (2020).","journal-title":"Curr. Opin. Microbiol."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1820292","DOI":"10.1080\/20002297.2020.1820292","article-title":"Oral Candida albicans colonization in healthy individuals: prevalence, genotypic diversity, stability along time and transmissibility","volume":"12","author":"Ger\u00f3s-Mesquita \u00c2","year":"2020","unstructured":"Ger\u00f3s-Mesquita, \u00c2. et al. Oral Candida albicans colonization in healthy individuals: prevalence, genotypic diversity, stability along time and transmissibility. J. Oral Microbiol. 12, 1820292. 10.1080\/20002297.2020.1820292 (2020).","journal-title":"J. Oral Microbiol."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/J.1600-0714.2007.00574.X","article-title":"One-year follow-up of the effect of fixed orthodontic treatment on colonization by oral candida","volume":"37","author":"G\u00fcnd\u00fcz Arslan S","year":"2008","unstructured":"G\u00fcnd\u00fcz Arslan, S., Akpolat, N., Kama, J. D., \u00d6zer, T. & Hamamci, O. One-year follow-up of the effect of fixed orthodontic treatment on colonization by oral candida. J. Oral Pathol. Med. 37, 26\u201329. 10.1111\/J.1600-0714.2007.00574.X (2008).","journal-title":"J. Oral Pathol. Med."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S1473-3099(24)00147-6","article-title":"An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial","volume":"24","author":"Pollock KM","year":"2024","unstructured":"Pollock, K. M. et al. An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial. Lancet Infect. Dis. 24, 829\u2013844. 10.1016\/S1473-3099(24)00147-6 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","article-title":"Controlled Human Malaria Infection of Healthy Adults with Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2","volume":"69","author":"Dejon-Agobe JC","year":"2019","unstructured":"Dejon-Agobe, J. C. et al. Controlled Human Malaria Infection of Healthy Adults with Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2. Clin. Infect. Dis. 69, 1377\u20131384. 10.1093\/cid\/ciy1087 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"ref92","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"Dissel JT","year":"2014","unstructured":"van Dissel, J. T. et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32, 7098\u20137107. 10.1016\/j.vaccine.2014.10.036 (2014).","journal-title":"Vaccine"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1089\/aid.2013.0076","article-title":"Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant t cell epitopes: Safety, immunogenicity, and feasibility in guinea-Bissau","volume":"29","author":"Rom\u00e1n VRG","year":"2013","unstructured":"Rom\u00e1n, V. R. G. et al. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant t cell epitopes: Safety, immunogenicity, and feasibility in guinea-Bissau. AIDS Res. Hum. Retroviruses. 29, 1504\u20131512. 10.1089\/aid.2013.0076 (2013).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","article-title":"Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial","volume":"19","author":"Abraham S","year":"2019","unstructured":"Abraham, S. et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 19, 1091\u20131100. 10.1016\/S1473-3099(19)30279-8 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1128\/IAI.73.2.999-1005.2005","article-title":"Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity","volume":"73","author":"Ibrahim AS","year":"2005","unstructured":"Ibrahim, A. S. et al. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 73, 999\u20131005. 10.1128\/IAI.73.2.999-1005.2005 (2005).","journal-title":"Infect. Immun."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1080\/21645515.2015.1044167","article-title":"Influenza vaccination in children primed with MF59\u00ae-adjuvanted or non-adjuvanted seasonal influenza vaccine","volume":"11","author":"Vesikari T","year":"2015","unstructured":"Vesikari, T., Forst\u00e9n, A., Arora, A., Tsai, T. & Clemens, R. Influenza vaccination in children primed with MF59\u00ae-adjuvanted or non-adjuvanted seasonal influenza vaccine. Hum. Vaccin Immunother. 11, 2102\u20132112. 10.1080\/21645515.2015.1044167 (2015).","journal-title":"Hum. Vaccin Immunother"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1086\/430952","article-title":"Mice with disseminated candidiasis die of progressive sepsis","volume":"192","author":"Spellberg B","year":"2005","unstructured":"Spellberg, B., Ibrahim, A. S., Edwards, J. E. & Filler, S. G. Mice with disseminated candidiasis die of progressive sepsis. J. Infect. Dis. 192, 336\u2013343. 10.1086\/430952 (2005).","journal-title":"J. Infect. Dis."},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025909","article-title":"Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis","volume":"6","author":"Luo G","year":"2011","unstructured":"Luo, G., Ibrahim, A. S., French, S. W., Edwards, J. E. & Fu, Y. Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One. 6 10.1371\/journal.pone.0025909 (2011).","journal-title":"PLoS One"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7270678\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7270678\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:12:26Z","timestamp":1766419946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7270678\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":98,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7270678\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-025-32488-8","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,9,5]]},"subtype":"preprint"}}